Immunomodulation of autoimmune inflammatory diseases like rheumatoid arthritis can be achieved by anti-inflammatory T2 cytokines such as interleukin (IL)-4 administered by gene therapy. In this study we investigated the efficiency of adeno-associated viruses (AAV) vectors in collagen-induced arthritis (CIA). After injection of AAV-LacZ in the tarsus area of mice, the expression of the transgene was localized in the deep muscles cells near the bone. LacZ expression was found in liver, heart and lung after i.m. injection of AAV-LacZ, showing a spread of the vector over the body. Anti-AAV neutralizing antibodies were detected in the serum after i.m. injection of AAV-LacZ, but they did not alter the transgene
Introduction
Rheumatoid arthritis (RA) is a serious, chronic inflammatory disease that results in joint destruction. The prevalence of RA in the general population ranges from 0.3% to 1%. The earliest joint abnormality is synovial tissue hypertrophy with neoangiogenesis. Inflammatory cells including T and B cells, plasma cells, neutrophils and macrophages migrate to the joint via the newly formed blood vessels. Changes in synovial membrane structure produce the rheumatoid pannus, which releases cytokines, enzymes and free radicals. These compounds ultimately destroy adjacent structures, primarily the cartilage and bone. 1 Over the past decade, extensive studies of cytokines in human RA and experimental RA models 2 have produced compelling evidence that IL-1 and TNF-␣ are the main mediators of the disease. 3 These two cytokines are produced in abundance in the synovial membrane and joint fluid. Neutralization of TNF-␣ by anti-TNF antibodies 4 or soluble TNF-receptors 5 has been shown to lessen inflammation-related abnormalities in patients with RA. A pivotal role of IL-1 in joint destruction has been demonstrated, and experimental arthritis has been successfully prevented by neutralizing IL-1 via the administration of anti-IL-1 antibodies, 6 soluble IL-1 receptors, 7 or the IL-1 receptor antagonist (IL-1ra). [8] [9] [10] We expression after re-administration of AAV-LacZ. Long-term IL-4 expression persisted 129 days after intra-muscular injection of 3.7 × 10 10 or 11.2 × 10 10 AAV-IL-4 p.p. (average 7.7 or 17.5 pg IL-4/mg proteins, respectively). More importantly, the treatment of CIA with AAV-IL-4 vector in mice produced a therapeutic benefit, since we show a diminished prevalence of the disease, a significant reduction in paw swelling, attenuated histological synovitis and a 10 days delayed onset of arthritis. This is the first evidence that AAV vector-mediated gene therapy using a T2 cytokine is efficient in an animal model of rheumatoid arthritis. Gene Therapy (2000) 7, 1930-1939. recently showed 11 that the type II IL-1 receptor, a decoy receptor for IL-1, exhibits anti-inflammatory effects in a model of RA, namely collagen-induced arthritis (CIA) in mice. 12, 13 Other proinflammatory monokines, including IL-12 and IL-18, may also be involved in RA. 14 The production of these monokines is perpetuated in part by T1-type cytokines such as IFN-␥ and IL-17. 15 Counterposing their effects are the T2 cytokines IL-4, IL-10, and IL-13, which modulate inflammation, both by directly inhibiting the production of TNF-␣, IL-1 and other mediators of RA, and by suppressing T1 functions. [16] [17] [18] In experimental models of arthritis, the increase in endogenous T2 cytokines coincides with subsidence of the disease. 19, 20 More importantly, we and others have shown that administration of IL-4, IL-13, or IL-10 ameliorates CIA, as well as other models of RA. 16, 17, [21] [22] [23] [24] To overcome the short half-life of cytokines in vivo, gene transfer has been investigated in various models of RA. 25 Adenoviral and retroviral vectors have been used successfully in several RA models to deliver genes encoding anti-inflammatory compounds such as IL-1ra, 8, 9, 26 TNF soluble receptor 7 or IL-10. 27 These vectors have a number of drawbacks, however. The major limitation of retroviral vectors is that they cannot infect nondividing cells. Adenoviral vectors can infect nondividing cells, but induce expression of antigenic viral proteins within the cells they infect, thus triggering an immune response against these cells and consequently rapid loss of transgene expression. Furthermore, we have shown in an earlier study that cell vector systems such as cells transfected in vitro, although cumbersome, can be used successfully in experimental arthritis. 16, 17, 21 Nonviral vectors are not immunogenic but until now have not allowed effective delivery and prolonged expression of transgenes. The adeno-associated virus (AAV) exhibits a number of advantages over these vectors. 25, 28 AAV is a small DNA virus of the Parvoviridae family. In human populations, the overwhelming majority of individuals have been exposed to the AAV, 29 which does not have known pathological effects. In addition to being safe, AAV vectors can infect a broad spectrum of host cells, at any phase of their division cycle. Furthermore, recombinant AAV vectors contain no viral genes but only the transgene flanked by two inverting terminal repeats (ITRs), which could package moderately sized transgenes, such as those encoding for cytokines.
The present study is the first to demonstrate that AAV vectors can have therapeutic anti-inflammatory benefits in CIA. Specifically, we showed that a recombinant AAV (rAAV) vector carrying the mouse IL-4 cDNA was clinically and histologically effective in CIA. Moreover, we report data on the immunogenicity and spread of AAV vectors in mice.
Results
Localization of transgene expression in vivo AAV-mediated gene transfer efficiency was evaluated in vivo by performing a single injection of rAAV particles. Ten DBA/1 mice were injected into the right tarsus area with 55 l of rAAV-CMV-LacZ containing 2.5 × 10 9 viral physical particles (p.p.). Each week for 8 weeks, mice were killed, and histological sections of the injected paws were prepared and stained for LacZ expression. Examination of serial tissue sections showed that LacZ expression was detectable starting the second week after the rAAV-CMV-LacZ injection persisting for the whole duration of the experiment (8th week). The histological analysis showed that transgene expression was located primarily in the deep muscle cells located near the bone. Examples of positive staining are shown in Figure 1 .
Immune response to AAV To investigate the immune response against the rAAV vector in vivo, transgene expression was evaluated in animals injected with rAAV-CMV-LacZ on two occasions. Five mice were injected with 1.25 × 10 10 p.p. rAAV-CMVLacZ into the left tibialis anterior muscle. Four weeks later, a second injection of 1.25 × 10 10 p.p. rAAV-CMVLacZ was given into the right tarsus area. The mice were killed 7 weeks after the first injection. Persistent, highlevel LacZ expression was found in the left tibialis anterior muscle (data not shown), as expected. Then, to evaluate transgene expression in animals previously challenged with the vector, LacZ was assayed in the right tarsus. A control group of four mice received NaCl as the first injection. As shown in Table 1 , only a slight, nonsignificant (t test), decrease in LacZ expression intensity was found in the right tarsus of rechallenged mice, as compared with the controls. Slightly increased neutralizing anti-AAV antibody levels were observed after 5 or 7 weeks in rechallenged animals, but the differences were not significant as compared with controls. Titers of neutralizing anti-AAV antibodies were not inversely correlated with LacZ expression in any of the individual mice. These results indicate that prechallenge did not affect AAV vector persistence in vivo.
Vector spread after rAAV injection in vivo
To evaluate the spread of the AAV vector, LacZ expression was investigated in tissues distant from the injection site. As shown in Figure 2 , all the animals given one or two injections exhibited LacZ expression at two or more of the distant sites studied: tarsus and muscle on the non-injected side, liver, spleen, heart and lung. Transgene expression was detected in the spleen in only one mouse, whereas LacZ expression was much higher in the liver than in the other tissues. This former result led us to perform another experiment to study the kinetics of AAV spread in the liver. Mice received a single injection of rAAV-CMV-LacZ in the tarsus area, and LacZ mRNA expression was assessed in the liver using RT-PCR at various timepoints. Figure 3 shows that LacZ mRNA expression was detected in the liver in one of two mice after 2 weeks, one mouse after 3 weeks, and two of two mice after 5 and 7 weeks. Taken together, these data suggest that the AAV vector spread widely throughout the body through the 7th week after vector administration with early, high-level transgene expression in the liver. 
Long-term expression of IL-4 in vivo
Before evaluating the therapeutic effect of AAV-mediated delivery of IL-4 in CIA, we determined the duration of transgene expression in vivo. Mice were injected with 3.7 × 10 10 or 11.2 × 10 10 p.p. rAAV-CMV-IL-4 in TA muscles and were killed 129 days later. We did not detect any IL-4 in the serum of injected mice (ELISA, data not shown). Conversely, Figure 4 shows the levels of IL-4 determined by ELISA in muscle lysates of rAAV-CMV-IL-4 injected mice or in saline-treated controls. Average IL-4 concentration for mice injected with 3.7 × 10 10 p.p. was 7.7 pg/mg protein (range 2.2-13.0 pg/mg protein), and for mice injected with 11.2 × 10 10 p.p., the average was 17.5 pg/mg protein (range 5.7-50.2 pg/mg protein). The IL-4 levels in saline-treated mice averaged 2.3 pg/mg protein, which was considered as the background value. Therefore, transgene expression could be clearly detected in mice more than 4 months after injection of the vector in vivo.
Modulation of clinical and histological CIA symptoms by rAAV-CMV-IL-4
We evaluated the ability of rAAV-CMV-IL-4 to prevent CIA in DBA/1 mice. Each mouse was injected with 1.3 × 10 10 p.p. into the right tarsus. Effects of rAAV-CMV-IL-4 were assessed in the injected paw by comparing clinical symptoms in the right, injected hind leg and in the left, noninjected hind leg. As shown in Figure 5a , clinical signs of inflammation were more marked at the site of rAAV-CMV-IL-4 injection, although the statistical analysis showed only a trend (P = 0.0878, ANOVA test). In control mice given an NaCl injection into the right tarsus
Figure 4 IL-4 expression following AAV-CMV-IL-4 injection in vivo.
Mice received one injection of 3.7 × 10 area, no differences were found between the right and left hind legs (Figure 5b ). We consequently sought to evaluate the effects of rAAV-CMV-IL-4 at a distance from the injection site. To this end, arthritis severity was evaluated in the three noninjected paws, either in the control group or in the group given rAAV-CMV-IL-4. Figure 6 shows that the control mice injected with NaCl developed severe arthritis with extensive joint inflammation. In contrast, the inflammation was less marked in the mice given rAAV-CMV-IL-4; the difference between two groups was statistically significant (P = 0.0329, ANOVA test). The maximal arthritic score mean (apex), evaluated in the three uninjected paws, was also signifiGene Therapy cantly reduced in the mice given rAAV-CMV-IL-4 as compared with the controls (5.25 ± 0.99 and 9.63 ± 1.19, respectively, P Ͻ 0.01, t test). Moreover, the prevalence of clinical CIA was significantly lower in the animals given rAAV-CMV-IL-4 ( Figure 7 ). Administration of rAAV-CMV-IL-4 was also associated with a marked, statistically significant delay in arthritis onset (Table 2 ) and with a reduction in the number of affected paws (data not shown). Histological studies provided clear-cut evidence of a statistically significant reduction in arthritis scores in the animals given rAAV-CMV-IL-4, either in both hind legs or fore legs (Table 2) . Conversely, some signs of inflammation were observed in the subcutaneous tissue (precisely at the point of injection) in the animals given rAAV-CMV-IL-4. In comparison, no histological Onset of clinical disease was evaluated considering the day of occurrence of arthritis in any of the four paws in each group. The delay after IL-4 treatment was statistically significant (*P Ͻ 0.05). a On day 64 after immunization, paws were subjected to histological studies involving examination of four sections per hind leg or fore leg, showing all the joints of each leg. In each mouse, the histological arthritis score (0-3) was the mean of the scores of each leg (** P Ͻ 0.01).
in TA muscle. Control mice received only NaCl (n = 11). 129 days later, IL-4 concentrations were evaluated by ELISA in muscle lysates and are expressed as pg IL-4 per mg of protein. Vertical bars represent mean ± s.e.m. *P Ͻ 0.01 versus NaCl (t-test).

Figure 5 Effect of rAAV-CMV-IL-4 on clinical signs of inflammation in the injected area. Mice were immunized with two intradermal CII injections given 21 days apart. Either rAAV-CMV-IL
cutaneous inflammation was observed in mice injected with 2.5 × 10 9 p.p. rAAV-CMV-lacZ in the tarsus area (not shown). Serum levels of anti-CII antibodies (IgG, IgG1, IgG2a) in the IL-4-treated group were not modified as compared with the control group (data not shown).
Discussion
The present study is the first to show that AAV gene therapy is clinically effective in a mouse model of RA. In addition, AAV-mediated gene transfer resulted in longlasting gene expression in vivo (more than 4 months) with only little vector-induced immunity. Gene therapy for rheumatic diseases has been widely investigated during the past few years. Before gene therapy can be used in polygenic diseases such as RA, important questions need to be answered, including which gene should be used, which vectors allow long-term transgene expression without inducing adverse effects, and where the vector/transgene system should be transferred.
We found evidence that CIA improves when IL-4 production is enhanced by injecting a transgene packaged in an AAV vector. The beneficial effects included decreases in the clinical and histological signs of arthritis, a reduced incidence of CIA, and a later onset of the disease. We chose IL-4 as the therapeutic agent because it is known to have anti-inflammatory properties in vitro and in experimental models of inflammatory diseases including RA. We and others have previously shown that transferring anti-inflammatory cytokine genes such as IL-4, IL-13 or IL-10 placed in viral vectors or in transfected cells resulted in anti-arthritic effects in experimental models of RA. 16, 17, 27, [30] [31] [32] [33] [34] The therapeutic effect of these cytokines reflects interlinked mechanisms. First, ex vivo studies of synovial cell cultures or synovial tissue explants from RA patients have established that IL-4 and IL-13 exert antiinflammatory effects related to direct inhibition of proinflammatory mediators such as IL-1, TNF, IL-6, and GM-CSF, 35, 36 MMP-1 and MMP-3. 37 These anti-inflammatory properties have also been demonstrated in vivo in CIA 16, 30 and in the TNF-transgenic mouse model. 17 Second, IL-4 can increase the production of IL-1ra, 35 IL-1RII 38 and TNF receptor, 39 thus directly blocking the proinflammatory effects of IL-1 or TNF. Furthermore, T2 cytokines can inhibit the development and production by T1 cells of several cytokines, most notably IFN-␥. Recently, IL-4 was shown to inhibit the production of IL-17, another T1 cytokine, in RA synovial tissue fragments cultured ex vivo. 15 Finally, IL-4-induced anti-inflammatory activity was associated with resolution of RA in several experimental models and was also effective in other inflammatory autoimmune diseases including diabetes 40 and multiple sclerosis. 41 The experiments reported here demonstrate that AAVmediated gene transfer provides long-lasting gene expression in vivo: IL-4 transgene was detected in the muscles of DBA/1 mice at least throughout the 129-daylong study period. This duration is highly sufficient in CIA. Human RA, however, is a chronic disease that would require long-lasting and adjustable transgene expression, as in inherited monogenic diseases. AAV vectors have been associated with long-term expression and a prolonged therapeutic effect in various animal models. For instance, LacZ expression has been detected for times longer than 6 months by using different administration routes to mice and rats, as intramuscular injections 42, 43 or oral administration. 44 Long-term expression was also obtained within the brain, 45 suggesting that AAV vectors might be of therapeutic interest in Parkinson's disease. 46 In canine models of hemophilia, factor IX delivered by AAV vectors allowed the reduction of the whole blood clotting time for longer than 17 months. 47 In nonhuman primates, epo expression allowed long-time correction of hematocrit levels. 48 Remarkably, in our study, we were able to detect IL-4 in mice muscles, and the cytokine levels depended on the quantity of rAAV-CMV-IL-4 particles injected. However, even if IL-4 administered using AAV vectors had a systemic therapeutic effect in CIA, we were unable to detect the cytokine in the bloodstream (data not shown). In another study, 22 IL-4 also proved difficult to detect in the serum by an ELISA, maybe because IL-4 bound to its specific receptor present on various activated cells (including T cells, macrophages, and endothelial cells), was undetectable by this technique.
The long duration of transgene expression associated with AAV vectors may be due to their low immunogenicity. In our study, no decrease in transgene expression was observed after a second injection of rAAV-CMV-LacZ. Actually, although we detected neutralizing anti-AAV antibodies in the animals after one or two injections of the vector, these neutralizing antibodies did not prevent AAV infection and LacZ expression. These data and an earlier study by Fisher et al 43 suggest that humoral immunity against AAV is too weak to induce the elimination of AAV-infected cells. The weak antibody response in our study may be due to the low immunogenic power of AAV capsid protein. A further advantage arises from the production and purification procedures employed, which yielded relatively pure vector preparations, with titer ratios of physical to infectious particles less than 100. Therefore, immunogenic reactions, elicited by large amounts of empty virus particles or other contaminants, could be less than favorable. Although promising results have been obtained using adenoviral vectors in various arthritis models, 30, 32, [49] [50] [51] [52] adenoviral vectors were often associated with loss of gene expression due to significant immunity directed against viral proteins. Furthermore, in contrast to adenoviral vectors expressing LacZ, AAV vectors did not induce humoral or cellular immune responses against the LacZ transgene. 43, 53, 54 However, in rabbits, AAV administration via the bronchial route induced a humoral response that impaired transgene expression following readministration of the vector. 55 These apparently conflicting results may be related to differences in the route of administration: in fact, the weaker immune responses may be associated with intramuscular route as compared with the intravenous, intraperitoneal or subcutaneous ones. 56 In addition, we observed in our study a cutaneous response in the tarsus area injected with rAAV-CMV-IL-4. But, as shown by histological analysis, this reaction was only confined to the injection site, whereas the neighbouring joint exhibited little or no inflammation. It would be interesting to study the intra-articular effect of rAAV-CMV-IL-4 in arthritis by injecting the vector directly into the joint. This approach is feasible, 57 but it was not applicable to our study since the volume containing 1.3 × 10 10 particles is too high to be injected intra-articularly. Anyway, one can wonder if the inflammatory effect of rAAV-CMV-IL-4 at the site of injection was induced by IL-4 or the vector. Consequently, we have studied the local histological effect of rAAV-CMV-lacZ injected in the tarsus area of mice, and we did not observe any sign of inflammation around the injection site (data not shown). This means that IL-4 may have a slight inflammatory effect in the proximity of its administration site. In this context, intra-articular injection of an adenovirus expressing the IL-4 gene was shown to worsen local inflammation in CIA but nevertheless protected against joint destruction. 30 Conversely, Boyle et al 31 found a significant reduction in paw swelling and articular destruction in rat adjuvant arthritis treated with intra-articular administration of retrovirus expressing IL-4. 31 Use of our approach in human RA will be within reach only when a number of gene therapy parameters have been improved and adapted to the human disease. In particular, RA, but not CIA, is characterized by spontaneous flares and remissions. Consequently, expression of the therapeutic transgene would have to be amenable to regulation. 58 This could be achieved by using either a promoter that can be stimulated by an external stimulus or an endogenous promoter that undergoes upregulation during the phases of disease activity.
The results of our study are the first evidence that antiinflammatory gene therapy using a T2 cytokine delivered by an AAV vector is effective in an RA model. Our data open up the possibility that AAV may be suitable as a vector for anti-inflammatory gene therapy in inflammatory autoimmune diseases.
Materials and methods
AAV vector construction, production, purification and titration rAAV-CMV-IL-4 vector was obtained from the pUC18-mIL4 plasmid, harboring the mouse IL-4 cDNA (Ingenius, BBG42), and pSMD2-mEpo AAV plasmid, where the mEpo cDNA expression is driven by CMV promoter. 42 First, mIL-4 cDNA sequence was PCR-amplified by using 5ЈAAGCTTACCTGCCATGGGT3Ј and 5ЈGAATTCGGATCCTCATTAC3Ј primers and further purified from agarose gel by using the Geneclean kit (BIO101) according to the manufacturer's instructions. Second, the pSMD2-AAV plasmid was obtained from the Gene Therapy pSMD2-mEpo, by replacing the mEpo sequence with a multi cloning site (mcs) containing MIuI, SalI, NsiI, EcoRV, PstI, NheI, XhoI, BglII sites. Third, mIL-4 sequence was inserted into the pSMD2 plasmid into the EcoRV site. The correct orientation of the inserted sequences and the whole pSMD2-mIL-4 resulting plasmid DNA ( Figure 8) were respectively checked by DNA sequencing analysis and agarose gel electrophoresis. rAAV-CMV-LacZ vector was obtained by the Genethon plasmid collection (Genethon vector collection http://www.egdr.org).
Large-scale production and purification of vectors were performed by using the triple transfection procedure of 293 cells, followed by CsCl density gradients or HPLC chromatography of cell lysates, as previously described. [59] [60] [61] [62] Basically, about 10 9 cells (70% of confluence) were transfected with a total amount of 0.8 g per 10 6 cells of each pXX6 (Ad E1 helper function) and 0.5 g of each pACG2.1 (Rep and Cap sequences) and pSMD2-mIL-4 plasmid DNA, which were previously complexed with 25 kDa PEI (Sigma Chemical, St Louis, MO, USA, 0.62 mm) in the presence of 130 mm NaCl (15 min at room temperature). Cells were harvested 40 h after transfection and cell lysates were obtained after three cycles of freezing and thawing (in 50 mm Hepes pH 7.5, 15 mm NaCl, and 1 mm MgCl 2 and CaCl 2 ), incubated with benzonase (Merck, Enzolab, Nogent s/Marne, France, 200 U/ml) for 15 min at 37°C, and centrifuged at 8000 r.p.m. for 15 min. In the CSCI purification protocol, crude lysates (4 × 3 ml) were loaded on to two-step CsCl (3 ml of each 1.5 and 1.35 g/ml) in four Optiseal centrifuge tubes (16 × 60 mm, 8.9 ml, Beckman, Fullerton, CA, USA). Gradients were spun at 67 000 r.p.m. for 6 h at 15°C in a 90Ti rotor. Gradients fractions (0.5 ml) containing vector particles were identified by dot blot by using specific transgene sequences (IL-4 or LacZ) as probes (see below). When the purification was performed by HPLC, cell lysates were chromatographed through a POROS 20SP or 50SP column (Perspective Biosystem) previously equilibrated with PBS. Lysates were loaded into the column by three sequential injections of 10-20 ml, and vectors were then eluted with a linear gradient of 0-1 m NaCl.
To determine physical particle concentration vector samples (10 l) were incubated with benzonase (2.5 U, 30 min) and proteinase K (100 g, 1 h at 37°C). DNA was then extracted with phenol/chloroform and ethanol precipitated, dissolved in 400 l of 0.4 NaOH, 10 mm EDTA and spotted on to nylon membrane (PALL Gelman). Membranes were washed with the SSC 2 ×, prehybridized in 0.5 m sodium phosphate buffer pH 7.4, 7% SDS, 1 mm EDTA, containing 100 g of salmon sperm DNA (1 h at 65°C), then hybridized overnight with the 32 P-radiolabelled probe in the same buffer. The intensity of the signal was measured with a STORM 840 (Molecular Devices/Amersham Pharmacia, Buckingham, UK) and normalized to the standard curve by using AAV plasmid DNA. The infectious particle concentration is determined by a variation of the procedure already described. 63 2 × 10 4 HeLa and HRC32 (harboring rep and cap sequences) cells were seeded in 96-well plates 24 h before to be co-infected with 10-fold serial dilutions (from 10 −2 to 10 −8 ) of rAAV stocks and Ad5 stock at MOI of 100. After 3 days, cells were lysed by addition of 50 l of 0.8 m NaOH, 10 mm EDTA, 0.5 ng d'ADN salmon sperm (ss) DNA (65°C, 30 min). Cell lysates were then loaded on to a nylon membrane, washed with 400 l of 0.8 m NaOH, 10 mm EDTA, and pre-hybridized in 0.5 m sodium phosphate buffer pH 7.4, 7% SDS, 1 mm EDTA, 100 g of ss DNA (65°C, 60 min), then hybridized overnight with the radio-labelled specific probe for the vector of interest. The infectious titer is expressed as the ratio of signals detected in HRC32 over Hela-infected cells with rAAV plus Ad5, corrected by the signal in samples infected with only Ad or rAAV alone or uninfected samples.
By using the above-described purification procedures, titers of vectors batches were: for rAAV-CMV-LacZ, 2.6 × 10 10 physical particles (p.p.) and 1.8 × 10 9 infectious particles (i.p.)/ml for batch No. 98031a (prepared with CsCl), and 2.2 × 10 11 p.p./ml and 3.5 × 10 9 i.p./ml, for batch No. A-DP5-15a (prepared with HPLC). For the rAAV-CMV-IL-4, 1.3 × 10 11 p.p./ml and 2 × 10 9 i.p./ml (batch No. A-DP5-98084a, prepared with HPLC).
Protein content determinations of crude lysates and purified fractions, revealed that both CsCl and HPLC purification procedures yielded vector purification factors Ͼ90% (data not shown).
Administration of rAAV-CMV-LacZ to mice
Five-to-7-week-old, DBA/1 male mice (Harlan Olac, Bicester, UK) were injected with rAAV-CMV-LacZ in NaCl using a microliter Hamilton syringe. For the evaluation of LacZ localization in vivo, mice received 2.5 × 10 9 p.p. in 55 l into the right tarsus area. Each week for 8 weeks, animals were killed and the entire hind legs were dissected and frozen at −80°C until LacZ staining. For the vector rechallenge experiment, 1.25 × 10 10 p.p. were injected in to the left tibialis anterior (TA) muscle in 57 l, and control mice received the same volume of buffer. Four weeks later, all the mice received 1.25 × 10 10 p.p. into the right tarsus area. Because of the small size of the tarsus, this second administration was divided into two injections of 28.5 l each, given on the same day. Seven weeks after the first injection, the mice were killed, and the left tibialis anterior, right tarsus, and other tissues were dissected and immediately processed for LacZ quantitative assay. In both experiments, mice were periodically bled using the retro-orbital technique.
LacZ staining of tissues
The frozen hind legs were placed in OCT embedding compound and snap-frozen in liquid nitrogen. Cryosections of the entire paw (12 m) were collected on glass slides, fixed in PBS with 0.8% glutaraldhehyde and 2.7% formaldehyde for 10 min, then rinsed in PBS for 10 min. For ␤-gal staining, the slices were incubated overnight with X-gal (1 mg/ml in staining buffer), at 37°C. The sections were then rinsed in PBS and counterstained with hematoxylin. Blue color was detected by light microscopy.
LacZ assay in tissues
To prepare protein lysates, hind legs were painstakingly dissected free of bone. The soft tissue fragments thus obtained were crushed and resuspended in 500 l lysis buffer (0.25 m Tris, pH 8). Others tissues were directly crushed and resuspended in 600 l (muscle) or 1 ml (other tissues) of lysis buffer in a 1.5 ml microfuge tube. The tissue and cell suspensions thus obtained were vortexed for 1 min at room temperature, then freeze/thawed five times. Lysates were cleared by two 10-min centrifugations, at 600 g and 15 000 g, respectively. The supernatants were stored at −80°C until assayed. LacZ assays were performed using a protocol adapted from the ␤-gal Assay Kit (Invitrogen, Leek, The Netherlands). Briefly, 60 l of lysate were incubated for 2 h at 37°C with 40 l of cleavage buffer (0.06 m Na 2 HPO 4 7H 2 O, 0.04 m Na 2 H-PO 4 H 2 O, 0.01 m KCl, and 0.001 m MgSO 4 7H 2 O, pH 7) and 35 l of ONPG (4 mg/ml). The reaction was stopped by adding 100 l of 1 m sodium carbonate. Absorbance was read at 405 nm on a spectrophotometer. The total protein quantity in each dissected tissue was determined by lysate absorbance at 280 nm. LacZ expression was expressed using the following formula: LacZ expression = OD 405 nm × protein quantity (mg).
RT-PCR for lacZ mRNA expression in liver Total mRNA was isolated from liver using 1 ml of Tri Reagent (Molecular Research Center, Cincinnati, OH, USA), in a final volume of 20 l, according to the manufacturer's instructions. RT-PCR was performed using the Access RT-PCR System (Promega, Madison, WI, USA), which provides RNA reverse transcription and cDNA amplification in a single reaction: 2 l of total RNA were added to 10 l of 5 × AMV/Tfl reaction buffer, 1 l of AMV reverse transcriptase (5 U/l), 0.3 l oligodT (1 g/l) (Genosys, Cambridge, UK), 1 l of dNTP (10 mm), 300 ng of sense and antisense specific primers (Genosys Biotechnologies, Cambridge, UK), 3 l of MgSO 4 (25 mm), and 1 l of Tfl DNA polymerase (5 U/l), in a final volume of 50 l. Primers for CMVlacZ (sense: 5Ј-GCGATGGGTAACAGTCTTGG-3Ј; antisense: 5Ј-ACATCCAGAGGCACTTCACC-3Ј) and ␤2-microglobulin (sense: 5Ј-TGACCGGCTTGTATGC TATC-3Ј; antisense: 5Ј-CAGTGTGAGCCAGGATATAG-3Ј) were used to generate 395 bp and 222 bp amplicons, respectively. Production and amplification of cDNA was achieved using a thermocycler (Thermo Jet, Eurogentec, Angers, France) with a 45-min step at 48°C (cDNA synthesis) followed by a 2-min denaturation step at 94°C, then by 35 amplification cycles; each cycle involved 1 min each at 94°C, 55°C, and 72°C. After amplification, 25 l of the PCR products were electrophoresed on 1% agarose gel containing ethidium bromide, then visualized using UV light.
AAV neutralizing antibody assay
Chinese hamster ovary (CHO) fibroblasts were grown in RPMI 1640 medium supplemented with glutamine and 7% heat-inactivated fetal calf serum. For the assay, cells were plated on a 96-well microtiter plate at 5 × 10 3 cells per well. The following day several dilutions of sample sera were incubated with 1.5 × 10 9 p.p. rAAV-CMV-LacZ for 1 h at 37°C. The medium was removed from the CHO cells. Diluted sera and virus were added and incubated for 5 h at 37°C. Fresh culture medium was then added.
Three days later, the cells were lysed, and LacZ activity was assayed using the ␤-gal assay kit (Invitrogen, Leek, The Netherlands) according to the manufacturer's instructions. A negative control serum was obtained from uninjected mice. Sera from mice bled 4 weeks after intradermal immunization with 2.2 × 10 10 p.p. rAAV-CMVLacZ in complete Freund's adjuvant (CFA) were used as the positive controls.
IL-4 assay in muscles TA muscles were injected with 3.7 × 10 10 or 11.2 × 10 10 p.p. rAAV-CMV-IL-4. The administration was divided in two injections of 337 l in each muscle. Control mice received the same volume of NaCl in both TA muscles. Muscles were dissected 129 days after injection and protein lysates were prepared in 600 l lysis buffer as described above. IL-4 concentration was determined in the lysates using a specific ELISA for murine IL-4 (Duoset; R&D Systems, Abingdon, UK) following the manufacturer's instructions. The total protein quantity in each dissected muscle was determined by lysate absorbance at 280 nm. IL-4 concentrations were expressed as pg of IL-4 per milligram of protein.
Collagen-induced arthritis induction and treatment regimen
Immunization of the mice and evaluation of the arthritis were done as previously described in detail. 64 Briefly, mice belonging to the DBA/1 strain, which is susceptible to collagen-induced arthritis (CIA), were injected intradermally at the base of the tail with 100 g of native bovine collagen type II (CII) emulsified in CFA. An intradermal booster was given on day 21 after priming with 100 g CII in incomplete Freund's adjuvant (IFA). The mice were monitored for evidence of arthritis using a blind procedure. Clinical severity of the arthritis in each joint or group of joints (toes, tarsus, ankle) was scored as follows: 0, normal; 1, erythema; 2, swelling; 3, deformity; and 4, necrosis. These scores were summed to obtain the arthritic score. The mean arthritic score on a given day was used to evaluate CIA severity. After the animals were killed, both hind legs and fore legs were dissected free and processed for histological studies, as described elsewhere. 64 The severity of synovial proliferation and the severity of inflammatory cell infiltration were each scored using a four-point scale (0-3, where 0 is normal and 3 severe). Individual sera were tested using a standard ELISA to look for antibodies to papain-solubilized native CII (total IgG, IgG1 or IgG2a). 65, 66 Treatment consisted of injection of 1.3 × 10 10 p.p. rAAV-CMV-mIL-4 in a volume of 100 l into the right tarsus area. Because of the small size of the tarsus, vector administration was divided into three injections of 33 l each, on days 8, 9 and 10 before CIA induction. Control mice received 100 l of NaCl into the right tarsus area using the same procedure.
Statistics
Results were compared using Student's t tests except when notified. The Kaplan-Meier method was used to analyze the occurrence of arthritis and the log rank tests to compare the two groups. For repeated measures (clinical scores), we used an analysis of variance method (ANOVA test). Statistical tests were run on the SPSS 8.0 software for Windows.
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